Road bumps and pitfalls for agricultural biotechnology by Deborah Delmer
The problems for biotechnology vary according to who you are—a large company that deals 
with important crops and developed-country farmers, a small private company, a public 
sector entity, university, national agricultural system or a CGIar institution—which I 
will come back to. as far as public/private partnerships are concerned, the rockefeller 
Foundation has seen success in collaboration with the Gates Foundation in creating such 
partnerships to tackle medical problems, such as aIDS, tB and malaria, but so far we 
have not had a single similar success for agriculture. Where you are is important also—the 
northern markets or australia is one story and genetically engineered (GE) crops are really 
taking off in some dynamic developing countries benefiting rich and poor farmers. In 
africa, where we spend a lot of our time, the problems are different again.
I am not in the private sector and can only guess as to what is worrying big industry 
at this point, and whether the Europeans will ever sort it out is an ongoing question that 
I will not dwell upon; however, there are signs of progress, with GE crops now planted 
in a few countries within the European Union.
the Next Generation
Some large companies are getting close to marketing the next generation of traits, beyond 
Bt and herbicide tolerance. The big questions will be:
• How do you capture value for quality traits?
• Will they require market segregation?
• Will genes for value-added traits be stacked with “conventional” insect resistance 
and herbicide tolerance?
Clearly, stacking is “in,” to the benefit of companies like Monsanto and companies 
like Pioneer need to form partnerships to obtain enough traits to stack effectively and be 
competitive. From the point of view of those of us who support projects on Golden rice 
and other nutritional improvements, it is hoped that the private sector will lead the way 
on stacking of traits and get the regulatory systems to accept them, because when you alter 
nutrition it is probable that little will be achieved by changing one trait at a time.
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Liability issues are of particular concern to smaller companies, with the effect of de-
laying the release of new products. Multinational companies have invested significant 
time in Latin america in particular and India in discussions on protection of intellectual 
property (IP). Interesting models are emerging from argentina and Brazil in conjunction 
with Monsanto; where patents have not been filed it may be possible to collect revenue 
from the end-user.
India is causing concern in demanding pricing structures, resulting in lowering of 
technology fees. On the positive side, large US companies see India—and China—as 
possible new markets including for GE products, which may have particular utility in 
the developing world. For the longer term, there is worry over competition from local 
producers of GE foods. 
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The large private-sector companies face many challenges in dealing with issues specific 
to the developing world and africa in particular. Clearly, these companies would like to 
build long-term markets for maize and cotton and are trying to balance humanitarian 
interests with commercial interests. We are trying to facilitate public/private partnership 
discussions, but the issues are complex and the cultures of the public and the private 
sectors are very different. It’s a huge challenge.
Where are the public sector and the small private sector in terms of bringing promising 
new GE products to the market-place? Where are the products listed by Peggy Lemaux1? 
Very few have come to market. Salient also is the issue of moving innovations efficiently 
downstream from universities; I agree with ralph Hardy2 that many scientists in public-
sector research lack business skills and know little about developing products that would 
have market-appeal for the common good.
Freedom to operate is a perpetual problem as is the high cost of regulation, particu-
larly so for smaller-market specialty crops that university and small private companies 
are interested in.
Public Perception
It is difficult to judge the degree to which negative public perception of GE foods remains 
a significant issue. It is noteworthy that very strong research programs on developing 
GE crops are in progress in China, India and Brazil. On one hand, EMBraPa in Brazil 
and India have a number of strong research institutes, but, on the other hand, there 
is a dearth of experience in bringing GE crops to market, at least by the public sector. 
Bt rice may be approved for commercial production soon in China and India and it is 
The cultures of the public and the private sectors are 
very different.
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hoped that Bt eggplant—an example of a new GE crop resulting from a public/private 
(Mahyco, India) partnership—will be available to farmers in India, Bangladesh and the 
Philippines late in 006.
The public sector has to strike the right balance between commercial and noncommercial 
delivery systems. It is the issue of public good and even at the rockefeller Foundation, 
which has a history in dealing with issues such as the Green revolution as well as noncom-
mercial aspects of agriculture, almost everything we talk about now is in terms of building 
dynamic national economies rather than stabilizing subsistence agriculture as the means of 
achieving sustainability. We are no longer talking in terms of just giving away GE crops. 
In any case, liability concerns and lack of adequate distribution systems preclude giving 
them away. Finding commercial models and developing seed systems beyond maize will 
be a challenge certainly in the poorer developing countries but may be a struggle also for 
minor crops in dynamic countries in the developing world.
as far as regulatory aspects are concerned, many countries started by following the US 
model with a conservative bent, placing restrictions where there was room for doubt. With 
experience, a risk vs. benefit philosophy has become more prevalent with the realization 
that if the approach is too strict no new products would see commercialization.
In the least developed countries where the rockefeller Foundation does a lot of funding, 
particularly in africa, we have to consider public perception and the NGOs. However, I 
am becoming more optimistic in this regard. I think that people are tiring of this debate 
and that there is opportunity for progress. a huge problem is weak research capacity in 
these small least-developed countries; seldom should you expect to fund projects for 
development in those countries in isolation. and it’s a challenge to find good partners in 
universities willing to train postdoctorals and build long-term research capacity in those 
countries. Finding the models for training and partners for projects is a challenge.
In terms of defining the relationship with the private sector, we’ve seen some public 
sector projects that are trying to repeat what large private sector companies are doing. For 
example, developing Bt maize for africa doesn’t make sense for the public sector when 
Monsanto has a perfectly good product. We have to be strategic and examine what the 
private sector will not tackle.
Many donors who are extremely timid about funding GE projects in the developing 
world, with the notable exception of the US agency for International Development, 
The rockefeller Foundation and, to some extent, the McKnight Foundation. For this 
reason, the CGIar centers are not at the cutting edge of biotech research. None of the 
Almost everything we talk about now is in terms of building 
dynamic national economies rather than stabilizing subsistence 
agriculture as the means of achieving sustainability.
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European donors are interested in funding this work. However, the good news is the 
Gates Foundation is quietly tip-toeing in and it is to be hoped that they will fund suc-
cessful projects that will encourage them to remain involved, which could significantly 
change the dynamics.
Intellectual Property
These issues may be simple or complicated. In Malawi, for example, developers of GE 
crops wouldn’t need to worry about patents. a developed-country counterpart interested 
in partnering with scientists in Malawi might be able to manage the IP, depending on how 
the project is structured. I was happy to see NaBC’s guidelines for field-research trials 
with GE crops (NaBC, 006). My biggest push in africa is not to convince countries 
to release GE crops to farmers. It is to encourage countries to let their scientists enter 
partnerships and develop new crops themselves that are locally appropriate. In order to 
participate in that development they have to be able to do simple research trials on site, in 
their own countries. In no other way will this move forward. africans, Indians, Chinese, 
all want ownership of these crops as they develop them and if those trials cannot be done, 
it will never happen. Simple research trials and understanding of how to do them safely 
and responsibly are required, at low cost and with minimal effort. It should not take  or 
3 years to obtain a permit for a simple trial, as it does now in Kenya.
Event-specific regulation is a real challenge. If you consider how difficult they are to 
breed and if we follow the US model of event-specific regulations, then we have a real 
problem in moving traits to locally adapted varieties of cassava and banana. We need a 
new model.
and we need regional harmonization in africa. although that continent will not be the 
breadbasket of Europe any time in the near future, there are tremendous opportunities for 
regional markets in africa with the growing urban populations. regional harmonization 
of biosafety regimes, quarantine restrictions, seed certification and so on will facilitate 
access to new regional markets.
On the sharing of IP, the Public Intellectual Property resource for agriculture (PIPra) 
has the objective of assisting public-sector institutions in garnering IP and strengthening 
management skills. PIPra now encompasses thirty-seven institutions in six countries. 
They will meet in the spring of 007 to explore bringing Europe into the fold, and more 
countries. They have got an IP database online where they list the licensing for all of their 
technologies. For anyone interested in obtaining vectors with freedom to operate, PIPra 
is now constructing them using its own public-sector IP. We hope that it will become 
available in a year or two.
My biggest push in Africa is to encourage countries to let their 
scientists enter partnerships and develop new crops themselves that 
are locally appropriate.
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The african agricultural technology Foundation is a fledgling organization learning 
how to broker technology transfer in africa. Some very smart africans running it have 
already had some success. Cambia Biosys has devised another model for possible open-
source licensing.
Good News
There is some good news and some bad news. The good news is the rapidly increasing 
global acreage planted to GE crops. and it’s noteworthy that GE crops are now being 
planted in five EU countries. Certainly poor farmers are beginning to benefit along with 
large farmers in some of the dynamic developing countries, as indicated in published 
data from South africa, China, India, Brazil and argentina. Interestingly, in africa it is 
happening in Burkina Faso; Monsanto is partnering tactfully with local scientists there in 
a series of trials of Bt cotton. They are moving the Bollgard-® trait into locally adapted 
varieties with very promising results. Working with their most advanced trait is smart 
management. This approach has changed the mindset of West african farmers to whom 
we have spoken. Suddenly they are saying, “Hey, if they have it in Burkina Faso then 
we must have it too.” and that is how this will work in africa: the people have to see it. 
and even though Monsanto will never get rich from Burkina Faso, it’s the kind of thing 
we need to see happen.
Not So Good
On the other hand, no GE food crop has been released for commercial use in China or 
India and it is unclear when this will happen, despite its expectation in recent years. In 
all of africa, South africa is the only country where GE crops are growing, but we are 
seeing movement in East and West africa: a lot more interest and a lot less fear. Illegal 
sale of GE seeds has been a problem, e.g. in India with Bt cotton and in Brazil with 
roundup ready® soy. It may be less of a problem with the next generation of GE traits, 
as companies learn how to handle this.
an article out of Pretoria, in South africa reported that poor farmers were doing well 
in the early days of Bt cotton when only one gin was accessible. The owners of the gin 
loaned the farmers the money to pay the high cost of the seed, and at the end of the season 
the loan was returned in kind when the farmers brought their cotton to the gin. Then, a 
second gin opened and the farmers said, “We’ll take the loan and the seed from the first 
gin but we’ll sell our cotton to the second gin.” Well, guess what, micro-credit is no longer 
available for these farmers. These are how institutional problems can create difficulties. 
We are still trying to get it right between the public and the private sectors.
The AATF is a fledgling organization learning how to broker 
technology transfer in Africa.
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In Summary
We need many skills to strengthen IP regimes. Similarly on regulatory issues, the Specialty 
Crops Initiative promises to provide cheaper field trials. The need to harmonize in West, 
East and South africa is becoming clear; individual countries are too poor to do this on 
their own. For a long time, 0% of the people have said this is great stuff and another 
0% have expressed distaste. In the middle is a vast disengaged majority who really don’t 
care, including many farmers in the developing world. I think that people are just tired 
of it. Let’s get on with it. Let’s just move on. It may not be an overflowing cup, but I’d 
say it’s more than half-full.
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